Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    Randomized, placebo-controlled, parallel group, double-blind, multi-center Phase III study to assess the inhibition of plaque formation of 0.1% octenidine mouthwash vs placebo in subjects with a gingival index ≤1.5

    Summary
    EudraCT number
    		 2017-001698-18
    Trial protocol
    		 DE   AT  
    Global end of trial date
    14 Sep 2018

    Results information
    Results version number
    		 v1(current)
    This version publication date
    05 Apr 2020
    First version publication date
    05 Apr 2020
    Other versions

    Trial information

    		 Close Top of page
    Trial identification
    Sponsor protocol code
    OML-III-B
    Additional study identifiers
    ISRCTN number
    		 -
    US NCT number
    		 NCT03378401
    WHO universal trial number (UTN)
    		 -
    Sponsors
    Sponsor organisation name
    Schülke & Mayr GmbH
    Sponsor organisation address
    Robert-Koch-Straße 2, Norderstedt, Germany, 22851
    Public contact
    Clinical trials information, Schülke & Mayr GmbH, Schülke & Mayr GmbH, +49 40 52100-0, info@schuelke.com
    Scientific contact
    Clinical trials information, Schülke & Mayr GmbH, Schülke & Mayr GmbH, +49 40 52100-0, info@schuelke.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    14 Sep 2018
    Is this the analysis of the primary completion data?
    Yes
    Primary completion date
    14 Sep 2018
    Global end of trial reached?
    Yes
    Global end of trial date
    14 Sep 2018
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    Demonstration of superiority of 0.1% octenidine mouthwash (OML, “Octenidin Mundspüllösung”) to placebo in the inhibition of plaque formation
    Protection of trial subjects
    The study was performed in accordance with the International Council on Harmonisation (ICH) Guideline for Good Clinical Practice (GCP, CPMP/ICH/135/95), the appropriate national regulations and the Declaration of Helsinki. Before any study-related procedures were performed, the investigator obtained written informed consent from all subjects. The investigator ensured that the subject was fully informed (verbally and in writing) about the aims, procedures, potential risks, discomforts, and expected benefits of the clinical study. The subject had ample time to ask questions and to decide whether or not to participate. Only subjects that met all study inclusion criteria and none of the exclusion criteria were entered in the study. Participation in the study was voluntary and all subjects had the right to withdraw from the clinical study at any time and for any reason without any disadvantages for their medical care.
    Background therapy
    		 -
    Evidence for comparator
    		 -
    Actual start date of recruitment
    11 Jan 2018
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    No
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Austria: 33
    Country: Number of subjects enrolled
    Germany: 67
    Worldwide total number of subjects
    100
    EEA total number of subjects
    100
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    100
    From 65 to 84 years
    0
    85 years and over
    0

    Subject disposition

    		 Close Top of page
    Recruitment
    Recruitment details
    		 Subjects were enrolled at 2 centers in Germany and 1 center in Austria. The first subject signed the informed consent form on 11-Jan-2018 and the last subject completed the study on 14-Sep-2018.

    Pre-assignment
    Screening details
    		 A total of 114 subjects were screened, of whom 14 subjects were screening failures.

    Period 1
    Period 1 title
    Overall trial (overall period)
    Is this the baseline period?
    		 Yes
    Allocation method
    Randomised - controlled
    Blinding used
    		 Double blind
    Roles blinded
    		 Subject, Investigator

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    		 OML arm
    Arm description
    		 0.1% octenidine mouthwash (OML)
    Arm type
    		 Experimental

    Investigational medicinal product name
    0.1% octenidine mouthwash
    Investigational medicinal product code
    Other name
    OML
    Pharmaceutical forms
    Mouthwash
    Routes of administration
    Oromucosal use
    Dosage and administration details
    Subjects performed 10 applications of OML (mouth rinse with 10 mL OML for 30 s) over 5 days (3 times on Day 1, twice daily on Days 2-4, once on Day 5).

    Arm title
    		 Placebo arm
    Arm description
    		 -
    Arm type
    		 Placebo

    Investigational medicinal product name
    Placebo
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Mouthwash
    Routes of administration
    Oromucosal use
    Dosage and administration details
    Subjects performed 10 applications (mouth rinse with 10 mL placebo for 30 s) over 5 days (3 times on Day 1, twice daily on Days 2-4, once on Day 5).

    Number of subjects in period 1
    		OML arm Placebo arm
    Started
    75
    25
    Completed
    74
    25
    Not completed
    1
    0
         Physician decision
    1
    -

    Baseline characteristics

    		 Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    OML arm
    Reporting group description
    		 0.1% octenidine mouthwash (OML)

    Reporting group title
    Placebo arm
    Reporting group description
    		 -

    Reporting group values
    		 OML arm Placebo arm Total
    Number of subjects
    		 75 25 100
    Age categorical
    Units: Subjects
        Adults (18-64 years)
    		 75 25 100
    Age continuous
    Units: years
        median (full range (min-max))
    		 24 (19 to 55) 24 (21 to 41) -
    Gender categorical
    Units: Subjects
        Female
    		 41 13 54
        Male
    		 34 12 46
    Gingival index
    Units: Subjects
        <=1.0
    		 71 24 95
        >1.0
    		 4 1 5
    Nicotine use
    Units: Subjects
        No
    		 65 16 81
        Yes
    		 10 9 19

    End points

    		 Close Top of page
    End points reporting groups
    Reporting group title
    OML arm
    Reporting group description
    		 0.1% octenidine mouthwash (OML)

    Reporting group title
    Placebo arm
    Reporting group description
    		 -

    Primary: Total mean plaque index after 5 days of treatment at Visit 2

    		 Close Top of page
    End point title
    		 Total mean plaque index after 5 days of treatment at Visit 2 [1]
    End point description
    The thickness and extension of plaque along the gingival margin were assessed using the plaque index (PI) according to Silness and Löe, 1964. Evaluation of the PI was limited to “Ramfjord teeth” (16, 21, 24, 36, 41, 44 or their replacement teeth 17, 11, 25, 37, 31, 45). For each of the 4 surfaces a grade from 0 to 3 was given. The total mean PI was the sum of the individual grades divided by the number of investigated sites.
    End point type
    Primary
    End point timeframe
    Day 5
    Notes
    [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: Results of the statistical analysis could not be entered in the system. The superiority of OML over placebo in inhibiting plaque formation was demonstrated using the van Elteren test stratified by gingival status at Visit 1 and center (1-sided p-value <0.0001; point estimate -0.88 [median difference, OML minus placebo]).
    End point values
    		 OML arm Placebo arm
    Number of subjects analysed
    75
    25
    Units: total mean plaque index
        median (full range (min-max))
    0.330 (0.00 to 2.13)
    1.210 (0.04 to 2.04)
    No statistical analyses for this end point

    Adverse events

    		 Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    From time of first study drug administration (Day 1) until end of treatment (completion of study, Day 5).
    Assessment type
    		 Non-systematic
    Dictionary used for adverse event reporting
    Dictionary name
    		 MedDRA
    Dictionary version
    20.1
    Reporting groups
    Reporting group title
    OML arm
    Reporting group description
    		 0.1% octenidine mouthwash (OML)

    Reporting group title
    Placebo arm
    Reporting group description
    		 -

    Serious adverse events
    		 OML arm Placebo arm
    Total subjects affected by serious adverse events
         subjects affected / exposed
    0 / 74 (0.00%)
    0 / 25 (0.00%)
         number of deaths (all causes)
    0
    0
         number of deaths resulting from adverse events
    0
    0
    Frequency threshold for reporting non-serious adverse events: 0%
    Non-serious adverse events
    		 OML arm Placebo arm
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    19 / 74 (25.68%)
    4 / 25 (16.00%)
    Nervous system disorders
    Dysgeusia
         subjects affected / exposed
    11 / 74 (14.86%)
    0 / 25 (0.00%)
         occurrences all number
    11
    0
    Headache
         subjects affected / exposed
    1 / 74 (1.35%)
    0 / 25 (0.00%)
         occurrences all number
    1
    0
    Migraine
         subjects affected / exposed
    1 / 74 (1.35%)
    1 / 25 (4.00%)
         occurrences all number
    1
    1
    Gastrointestinal disorders
    Tongue discolouration
         subjects affected / exposed
    4 / 74 (5.41%)
    0 / 25 (0.00%)
         occurrences all number
    4
    0
    Dental discomfort
         subjects affected / exposed
    0 / 74 (0.00%)
    1 / 25 (4.00%)
         occurrences all number
    0
    1
    Oral discomfort
         subjects affected / exposed
    1 / 74 (1.35%)
    1 / 25 (4.00%)
         occurrences all number
    1
    1
    Reproductive system and breast disorders
    Dysmenorrhoea
         subjects affected / exposed
    0 / 74 (0.00%)
    1 / 25 (4.00%)
         occurrences all number
    0
    1
    Skin and subcutaneous tissue disorders
    Pruritus
         subjects affected / exposed
    1 / 74 (1.35%)
    0 / 25 (0.00%)
         occurrences all number
    2
    0

    More information

    		 Close Top of page

    Substantial protocol amendments (globally)
    Were there any global substantial amendments to the protocol? No

    Interruptions (globally)
    Were there any global interruptions to the trial? Yes
    Date
    Interruption
    Restart date
    23 Mar 2018
    The study was halted, since metallic (zinc) contaminants were found in a substance that was used for the solution of the study drug flavors. All study drug bottles at centers that were still recruiting subjects at this time were controlled for visible particles using the 4-eye principle, and if found, contaminated bottles were quarantined, and the center was supplied with new study drug. Study drug with no visible particles was considered safe. Patients who had already completed the study were informed about the study drug contamination.
    07 May 2018

    Limitations and caveats
    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 07 08:38:30 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA